CORRIXR THERAPEUTICS
Live / Allowed — Fifth extension granted (statement of use) (as of 13 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 31 Mar 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97340109
- Mark type
- Word mark
- Filed
- 31 Mar 2022
- Published for opposition
- 15 Aug 2023
- Attorney of record
- Gregory S. Bernabeo
Goods and services
- Class 042 — Scientific and technological services: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development; research and development of therapeutics pharmaceuticals using gene editing; medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy
Owner
- CorriXR Therapeutics, Inc., Newark, DE, US
- CorriXR Therapeutics, Inc., Wilmington, DE, US
Prosecution history
- 13 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2026 — SOU EXTENSION 5 GRANTED
- 10 May 2026 — SOU EXTENSION 5 FILED
- 10 May 2026 — SOU EXTENSION 4 GRANTED
- 10 Oct 2025 — SOU EXTENSION 4 FILED
- 10 Aug 2026 — NOTICE OF REVIVAL - E-MAILED
- 10 Aug 2026 — PETITION GRANTED - EXTENSION REQUEST FILED
- 28 Jul 2026 — TEAS RESPONSE TO PETITION DEFICIENCY RECEIVED
- 01 Jul 2026 — INCOMPLETE PETITION NOTICE MAILED
- 24 Jun 2026 — ASSIGNED TO PETITION STAFF
- 26 Nov 2025 — PETITION TO REVIVE-RECEIVED
- 23 Jun 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 26 Nov 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 26 Nov 2025 — NOTICE OF REVIVAL - E-MAILED